Associated Papers
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
41484121 (PubMed )
Supplement: 41467_2025_68076_MOESM1_ESM.pdf
Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights.
Anaya YA et al.
International Journal of Molecular Sciences, 2025
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
37922692 (PubMed )
Supplement: mmc1.docx
Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.
Ambrosini-Spaltro A et al.
Current Oncology (toronto, Ont.), 2023
[Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].
Zhang H et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2022
Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.
Huang RSP et al.
Journal for Immunotherapy of Cancer, 2021
34130989 (PubMed )
Supplement: jitc-2021-002558supp001.pdf
Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling.
De Andrade JP et al.
Annals of Surgical Oncology, 2020
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Pozdeyev N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Leonetti A et al.
Cancer Treatment Reviews, 2018
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Gautschi O et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2015
Select a paper to view details